Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind dose-ranging study of Dysport RU for moderate to severe glabellar lines
2010-019085-82Phase 2Completed
- Sponsor
- Ipsen
- Start
- Dec 2010
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of botulinum toxin type A in glabellar furrowing (5 arms), sponsored by Ipsen. Primary endpoints: Investigator live responder rate at Day 29 and Subject self-assessment responder rate at Day 29. Started Dec 2010; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
glabellar furrowing
Beyond the preview
Go deeper on 2010-019085-82.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019085-82.